Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23824437 | 1.00 | CTSL (0.37) | CTSLCTSB | |
| SCHEMBL23824440 | 1.00 | CTSL (0.37) | CTSLCTSB | |
| SCHEMBL30310648 | 0.90 | CTSL (0.47) | CTSLCTSB | |
| SCHEMBL29063038 | 0.88 | CTSL (0.48) | CTSLCTSB | |
| SCHEMBL24690561 | 0.86 | — | — | |
| SCHEMBL23836465 | 0.84 | CTSL (0.36) | CTSLCTSB | |
| SCHEMBL25134601 | 0.84 | CTSL (0.36) | CTSLCTSB | |
| SCHEMBL24696826 | 0.83 | CTSL (0.39) | CTSLCTSB | |
| SCHEMBL23824515 | 0.83 | CTSV (0.36) | CTSLCTSB | |
| SCHEMBL23824512 | 0.83 | CTSV (0.36) | CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4366831-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| WO-2024081318-A1 | ANTI-VIRAL COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-20240109871-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-04-04 | — | — | US | disclosed |
| WO-2024059087-A1 | 3-(1H-INDOLE-2-CARBONYL)-6,6-DIMETHYL-N-((S)-1-OXO-3-((S)-2-OXOPYRROLIDIN-3-YL)P ROPAN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE DERIVATIVES AS MPRO INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-03-21 | — | — | WO | disclosed |
| US-20240018126-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-01-18 | — | — | US | disclosed |
| WO-2024010794-A1 | ANTI-VIRAL COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-11851422-B2 | Anti-viral compounds | ALIGOS THERAPEUTICS, INC. | 2023-12-26 | — | — | US | disclosed |
| WO-2023245162-A2 | COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION | TRAWSFYNYDD THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023125846-A1 | COMPOUND FOR PREVENTING AND TREATING CORONAVIRUS INFECTION, CONJUGATE THEREOF AND METHOD THEREFOR | 苏州爱科百发生物医药技术有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| WO-2022266363-A1 | PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-12-22 | — | — | WO | disclosed |
| US-20220402896-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2022-12-22 | — | — | US | disclosed |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-12-13 | — | — | US | disclosed |
| CN-115043900-A | Peptide-like compound and application thereof in preparation of 2019-nCoV main protease inhibitor | 深圳博瑞医药科技有限公司 | 2022-09-13 | — | — | CN | disclosed |
| US-20220162194-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2022-05-26 | — | — | US | disclosed |
| US-11312704-B2 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-04-26 | — | — | US | disclosed |
| WO-2021252644-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-20210355111-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2021-11-18 | — | — | US | disclosed |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11124497-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2021-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312704-B2 | Inhibitors of cysteine proteases and methods of use thereof | CTSV, CTRL, CTSL | CTSL 3/4885CTSB 28/4885 |
| US-20220162194-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | CTSL 3/4885CTSB 28/4885 |
| US-20220402896-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | CTSL 3/4885CTSB 28/4885 |
| US-20210355111-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSV, CTSL | CTSL 3/4885CTSB 32/4885 |
| US-11124497-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | CTSL 3/4885CTSB 24/4885 |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | CTSL 3/4885CTSB 32/4885 |
| US-11851422-B2 | Anti-viral compounds | EIF2AK2, ZC3HAV1, HAVCR2 | CTSL 1088/4885CTSB 829/4885 |
| US-20240018126-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | CTSL 1088/4885CTSB 829/4885 |
| US-20240109871-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | CTSL 1088/4885CTSB 829/4885 |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | CTSL 3/4885CTSB 32/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | CTSL 2/4885CTSB 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.